The firm has inked a debt financing agreement with Blue Owl Capital and will use the funds to launch ITM-11in the US market following approval.

NEW YORK – The European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of Autolus Therapeutics' autologous CD19-directed CAR T-cell therapy Aucatzyl ...

Scientists are seeking new grant opportunities, founding their own for-profit ventures, and exploring other approaches to ...

Investigators presented interim data from a Phase III trial of Lenmeldy in patients with the late juvenile form of disease at ...

Multiple first-in-human trials showed functional and biomarker improvements in early data reported at ASGCT's annual meeting.

The firms launched the global Phase II bladder cancer trial for autogene cevumeran after seeing early success in pancreatic ...

NEW YORK – CAR T-cell therapy is potentially lifesaving for patients with blood cancer, but it is also labor-intensive and difficult to access for those who must travel for hours to the nearest ...

NEW YORK – The US Food and Drug Administration this week cleared two investigational new drug applications from Avenzo Therapeutics, giving it permission to begin Phase I/II clinical studies of the ...

NEW YORK – Several in-progress studies have given Maija Hollmén, a researcher at the University of Turku in Finland, reason to believe that bexmarilimab, a Clever-1 inhibitor she helped develop, could ...

NEW YORK – Researchers are exploring whether an artificial intelligence-based tool can assist pathologists in evaluating HER2 expression by immunohistochemistry (IHC) and improve accuracy when scoring ...